Lukang shareholders approve governance revisions at extraordinary meeting

Shandong Lukang Pharmaceutical Co., Ltd. held its second extraordinary general meeting of shareholders for 2025 on October 10, 2025, with 249,755,048 shares, representing 27.7916% of total voting shares, in attendance. The meeting, chaired by chairman Peng Xin, approved all proposed resolutions, indicating strong shareholder consensus on the company's future operational framework.

Key resolutions passed include the cancellation of the supervisory board and revisions to the articles of association, which received 95.5152% of votes in favor. Shareholders also approved revisions to various governance documents, such as the shareholder meeting rules, board of directors meeting rules, and independent director work system, with approval rates consistently above 95.5%.

Further resolutions, including revisions to the external guarantee management system, external investment management system, and management measures for the use of raised funds, also passed with significant support. The "Cancellation of the Supervisory Board and Revision of the Articles of Association" was a special resolution requiring a two-thirds majority and was successfully approved. Beijing Tongshang Law Firm confirmed that the meeting's procedures complied with relevant laws and regulations.